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Abstract
Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility
in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (.90%). Since
new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as
nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on
solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules
per dendrimer) was achieved with a mixture of chloroform:methanol 50:50 v/v solution pH 3. In addition, to explore the
possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of
dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological
changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological
brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes
were observed when larvae were treated with the complex.
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Introduction
The antipsychotic drug risperidone, 3-[2-[4-(6-fluoro-1,2-benzi-
soxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-
pyrido[1,2-a] pyrimidin-4-one (Risp), belongs to the chemical class
of benzisoxazole and it is one of the drugs most widely used in the
treatment for autism spectrum disorders (ASD) [1,2]. ASD, which
occur in 1 out of 150 individuals [2], include different
neurodevelopment disorders that manifest mainly in the earlier
years of life [3], affecting language, communication and reciprocal
social interaction development [4]. Risp has low solubility in
aqueous medium and, when orally administered, exhibits low
bioavailability due to extensive first-pass metabolism and high
protein binding (.90%) [5]. Moreover, non-targeted delivery
usually results in numerous side effects. Since Risp target organ is
the brain, it is necessary not only to develop a strategy to improve
drug bioavailability, by avoiding first-pass metabolism, but also
to achieve the desired drug concentration at the site of action,
thus reducing undesirable side effects [1]. In the last years,
strategies with chemical therapies, particularly the design of nano-
structured drug carrier systems [6], have been proposed to
overcome these issues regarding ASD treatment. However,
these kinds of carriers (plain, ultradeformable, stealth, pH-
sensitive liposomes, immunoliposomes, nanoparticles and dendri-
mers) must be carefully designed and/or chosen because their
pharmacokinetics, biodistribution, and tissue selectivity depend
exclusively on the nanocarrier structure [1,7–9].
In this sense, dendrimers are exceptional polymers presenting
important advantages over conventional linear or branched ones
such as polyethylene terephthalate or comb polymers, respectively
[10,11]. These advantages include monodispersity [12], controlled
size in the range of nanometers, controlled number of surface
groups, and extremely high area/volume ratio. Only intermediate
generation (3.5–5 G) dendrimers are suitable drug carriers, with
structures open enough to enable the loading and subsequent
release of molecules in a controlled fashion [13–15]. Since, in the
last years, PAMAM dendrimers have been found to be useful to
improve the solubility of low aqueous soluble drugs [16,17], the
present work aims to enhance Risp solubility by means of
PAMAM dendrimers. On the other hand, we used the zebrafish
(Danio rerio) as an ideal model to study developmental neurobiology
and other fields of biomedicine. The zebrafish is a teleost of the
Cyprinid family, with several advantageous features for use in the
laboratory: its small size (no more than 5 cm in adults) allows easy
maintenance of several individuals with relatively low costs;
females lay a large number of eggs; embryos develop rapidly
and are semitransparent 24 hours post-fertilization (hpf); and
embryos have a sequenced genome and numerous mutant and
transgenic lines [18–22].
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Thus, our proposal was the optimization of Risp complexation
with PAMAM dendrimers Generation 4.5 (DG4.5) at different
solvent concentrations, pH and molar relationship (Figure 1). In
addition, we analyzed the in vivo effects of risperidone and DG4.5-
Risp complexes on heart rate and brain development of zebrafish
larvae.
Materials and Methods
Materials
Poly(amidoamine) (PAMAM) dendrimer G4.5 (–COOH) (mo-
lecular weight = 26,258 g/mol, 128 carboxyl end groups) (DG4.5)
was purchased from Sigma–Aldrich, Argentina. Risperidone
(Risp) 99.0% was donated by Janssen Cilag Laboratory,
Argentina. All other reagents used were of analytical grade.
Preparation of DG4.5-Risp Complex
DG4.5 was obtained as previously [9]. Briefly, DG4.5 was
combined with a specific amount of Risp in methanol solution at
1:100 and 1:250 DG4.5:Risp molar ratios, and methanol was
immediately evaporated in a Speed Vac SAVANT at 25uC for
15 min (1010 SAVANT). After evaporation, Risp and PAMAM
DG4.5 were incubated with 1 ml of: a) chloroform:methanol
70:30; b) chloroform:methanol 50:50; c) chloroform:methanol
90:10; d) chloroform:methanol 50:50 pH 3; e) chloroform:metha-
nol 50:50 pH 6; f) chloroform:methanol 50:50 pH 9; g) chlor-
oform:methanol 50:50 pH 3 with additional drying; h) chloro-
form:methanol 50:50 pH 6 with additional drying; or i)
chloroform:methanol 50:50 pH 9 with additional drying. All
incubations were carried out for 48 h at room temperature (20uC)
with continuous stirring. Finally, solvents were completely
evaporated in a Speed Vac SAVANT. The solid residues obtained
were dissolved in 0.1 ml of phosphate buffer (PBS), at room
temperature, and centrifuged at 10,0006g for 10 min, in order to
separate the DG4.5-Risp complexes (DG4.5-Risp) (soluble Risp)
from the non-incorporated Risp (insoluble) (Figure 2). Complex’s
pH was adjusted to physiological pH with phosphate buffer PBS
7.4. The drug does not precipitate as it is incorporated into
dendrimers and dendrimers are water soluble.
If there were traces of MeOH and/or chloroform, they were
determined prior to preparing the final solution complexes. Steps
followed were: samples of each condition, in quintuplicate, were
vacuum dried in a Speed Vac SAVANT 10010 until dryness. Two
sets of samples were prepared in a parallel form. One set of
samples was submitted to an additional drying procedure in an
oven for 2 h at 40uC, the other set remained at room temperature,
and was used as a control. Afterwards, all samples were suspended
in the buffer solution and quantification of Risp was stated as in
section 2.3. All samples achieved the same result for each
condition between sample and control, confirming that the second
step was unnecessary and the absence of solvent present was
confirmed.
Risperidone Quantification
The amount of Risp was quantified by measuring the
absorbance at 280 nm with a UV–Vis NanoDrop1000. The
calibration curve of Risp in PBS was linear in a concentration
range of 0.1–100 mg/ml (r2 = 0.99) (Figure 3) [23,24]. DG4.5 does
not absorb at this wavelength (see Figure 4).
From absorbance vs. wavelengths graphics at different concen-
trations like Figure 5, a double reciprocal plot of 1/absorbance
versus 1/Risp concentration was calculated and linear regression
was linear, and the binding constant (k) estimated from the ratio of
the intersection to the slope was k = 4 [25,26].
In Vitro Release Studies
In vitro release of Risp from DG4.5-Risp complexes was studied
in PBS by using a micro-dialysis eppendorf tube diffusion
technique, by replacing the top internal flap-cover of a 0.5-ml
eppendorf tube with a dialysis membrane. This technique was
implemented and adapted to overcome micro-quantities of the
released drug. DG4.5-Risp complexes were sealed into the micro
dialysis eppendorf tube (MW cut-off: 12000 from Sigma-Aldrich,
Argentina) and incubated in PBS under continuous stirring. The
Risp release experimental design consisted of collecting aliquots at
pre-determined time intervals from the incubation medium, and
storing them at 4uC for quantitative analysis. Each aliquot
withdrawn is replaced afterwards by an equal volume of fresh
medium to maintain volume and to be considered within the
calculus. On the other hand, pH and temperature are controlled
to ensure they remain unchanged. The assay was repeated three
times and the amount of released Risp was determined by
absorbance at 280 nm, as described in Section 3.3. Data were
analyzed with GraphPad Prism 5 t-test.
Characterization of DG4.5-Risp Complexes
The spectra of the collected samples were characterized placing
1 ml of each of the residues into the attachment plate to measure
attenuated total reflectance (ATR). The determinations were
carried out in a spectrophotometer IRAffinity-1 Fourier Trans-
form Infrared Compact Shimadzu. After 25 scans in the range of
650 cm21 to 4000 cm21, the spectrum was withdrawn with a
resolution of 0.5 cm21. The IR spectra were analyzed with
solution software, version 1.50, supplied by the manufacturer.
Mean particle size and zeta potential of the complexes were
determined by dynamic light scattering with a Nanozetasizer
(Malvern Instruments, Malvern, Worcestershire, UK).
In Vivo Studies: Animals
Adult zebrafish (Danio rerio) used as breeding individuals belong
to the AB line, provided by the Department of Cell Biology and
Pathology, University of Salamanca (Spain) for histological assays.
The animals were kept in tanks at 28uC on a 14/10 h light/dark
cycle as previously established [18]. In this study, embryos refer to
zebrafish prior to hatching (0–3 dpf), while larvae refer to post-
hatching animals (over 3 dpf). Embryos were obtained from
natural mating, and all embryos/larvae used in these experiments
were reared at 28.5uC on a 14/10 h light/dark cycle in
conditioned E3 medium (NaCl 0.29 g/l, KCl 0.012 g, CaCl2
Figure 1. Dendrimer-Risperidone complex. Scheme of Risp
complexation with PAMAM dendrimers Generation 4.5 (DG4.5)
at different solvent, pH and molar relationship.
doi:10.1371/journal.pone.0090393.g001
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0.036 g/l and MgSO4 0.039 g/l in deionized water, and 50 ppb
methylene blue (Panreac) to inhibit fungal growth).
Ethics Statement
The animals were handled following the European Union
directives (86/609/EEC and 2003/65/EC) and Spanish legisla-
tion (RD 1201/2005, BOE 252/34367-91, 2005). Full details of
the study were approved by the Bioethics Committee of
Salamanca University (CBE/30/07/08). The animals were
anesthetized by a tricaine methanesulfonate solution and all
efforts were made to minimize suffering.
Embryo Collection
The evening before spawning, breeding pairs of specimens were
transferred to rearing tanks. These tanks were kept at 28.5uC. The
first light stimulus after the dark cycle induced egg lay. The eggs
obtained were prepared in petri dishes in E3 medium. Only
fertilized eggs in good condition were selected for further
treatment; the others were discarded. The characteristics of eggs
were determined with a stereomicroscope (Leica Zoom 2000).
Exposure to Risperidone and PAMAM Complexes
Risperdal tablets (Janssen Cilag Laboratory, 2 mg Risp) were
dissolved in E3 medium and prepared as a 0.5, 5 and 25 mM
solution. The larvae were divided into four groups and then
treated with i) Risp at 4 dpf for 24 h, ii) Risp at 6 dpf for 24 h, iii)
DG4.5-Risp at 4 dpf for 24 h, and iv) DG4.5-Risp at 6 dpf for
24 h, or v) medium (controls). Larvae were exposed to 5 mM Risp
for 24-h periods and subsequently rescued into a preconditioned
E3 medium (Figure 4 A and B). Buffered solution was pH 7.4 and
it was administered to each well under treatment where larvae
were, as indicated in Figure 4 B.
Heart Rate Measurements
The heart rate was assessed on 8 and 10 dpf. Control and
experimental zebrafish larvae were individually transferred to a
depression slide with methylcellulose and placed under a binocular
microscope. The heart rate was determined by counting the
number of beats every 15 s and recorded as beats per minute
(bpm) (see Video S1). Experiments were performed thrice on three
larvae per group for each time point [27].
Preparation of Histological Sections
For the fixation of samples, both treated and control animals
were anesthetized by a tricaine methanesulfonate solution (MS-
222, Sigma) at 0.3 g/l. Samples were then fixed by immersion in
4% v/v paraformaldehyde in PBS, pH 7.4 for 24 hours at 4uC.
Following fixation, paraformaldehyde was removed with five
washes of 5 minutes in PBS. Then, the samples were embedded in
a mixture of agar 1.5% and sucrose (Panreac) 10% in PBS. Such
mixture was heated and added to the plastic molds in which the
animals were targeted. After the mixture was solidified, the larvae
were cryoprotected in a 30% w/v sucrose solution in PBS for 24 h.
Agar blocks containing cryoprotected larvae were frozen in a
Figure 2. Preparation of DG4.5-Risp Complex. DG4.5 was combined with a specific amount of Risp in methanol solution and
methanol was immediately evaporated. All incubations were carried out for 48 h at room temperature with continuous stirring. Finally, solvents
were completely evaporated. The solid residues obtained were dissolved in 0.1 ml of buffer PBS, at room temperature, and centrifuged at 10,0006g
for 10 min, in order to separate the DG4.5-Risp complexes (soluble Risp) from the non-incorporated Risp (insoluble).
doi:10.1371/journal.pone.0090393.g002
Figure 3. Risperidone quantification. Scheme shows the determination of number of Risp molecules per dendrimer. The amount of
Risp was quantified by measuring the absorbance at 280 nm with a UV–Vis spectrophotometer.
doi:10.1371/journal.pone.0090393.g003
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cryostat (Microm HM 560) and then cut at 228uC in 10-mm-thick
parasagittal serial sections, which were collected on gelatinized
slides and stored at 220uC until further use. We performed 55
histological sections and larvae were analyzed three times (n = 3) at
10 dpf [27].
Hematoxylin-Eosin Staining
Histological sections were obtained as mentioned above and
stained with hematoxylin-eosin to observe possible morphological
changes. Briefly, the technique involves immersing the sections in
eosin for 1 minute, then washing with water every 30 minutes and
further incubating for 1 minute in hematoxylin. Finally, the
samples were dehydrated in ethanol of increasing concentration
for 5 minutes each, ending with three tanks of xylene, for 3
minutes each. The slides were mounted in Entellan (Merck KGaA,
Darmstadt, Germany) for analysis and storage. Images of
hematoxylin-eosin staining were taken in a light microscope
(Olympus Provis AX70) coupled to a digital camera (DP70,
Olympus).
Finally, to adjust the brightness and contrast to those observed
directly under the microscope, Adobe H Photoshop CS2 H version
9.0 (Adobe Systems) was used [27].
Immunohistochemistry in Tissue Sections
The sections were washed three times in PBS for 10 min to
rehydrate and remove the agar. They were incubated for 1 h at
room temperature (RT) in non-immune serum (Sigma) 5.0%,
detergent Triton X-100 (Sigma) 0.2% and 1.0% DMSO in PBS.
The serum used was made into the species of the secondary
antibody.
Then, the primary antibodies were added and incubated
for 24 hours at RT. After this incubation, the excess antibodies
were removed with three washes with PBS and then the sections
were incubated with the corresponding secondary antibodies
Figure 4. Timeline representing the stage specificity of the effects of risperidone and DG4.5-Risp in developing zebrafish. Larvae
were exposed to 5 mM risperidone or DG4.5-Risp for 24-h periods from 4 dpf or 6 dpf and subsequently rescued into a conditioned E3 medium (A).
Schematic representation of the in vivo treatment (B).
doi:10.1371/journal.pone.0090393.g004
Figure 5. Evaluation of the Dendrimers-Risperidone complex
formation. Absorbance Spectrum DG4.5-Risp (green) and free
Risp (black) under experimental conditions determined as
optimum.
doi:10.1371/journal.pone.0090393.g005
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conjugated with the appropriate fluorochrome for 1 h at RT. The
secondary antibody was removed with three washes of 10 minutes
each in PBS with fish gelatin 0.4% (Sigma-Aldrich).
In order to mark cell nuclei, tissue sections were incubated in
49,6-diamidine-2-phenylindole (DAPI, Sigma) at a 1:10,000
concentration for 7 minutes at RT, and then washed three times
of 10 minutes each in PBS.
Antibodies Used
-Polyclonal anti-calretinin (CalR) antibody 7696 (# 6B3 Swant,
Bellinzona, Switzerland) at a 1:10,000 concentration. This
antibody has been widely used in the study of the neuroanatomy
of teleosts, in adult animals as well as in embryos, larvae and
juveniles [28,29]. Secondary antibody labeled with Cy3 (red) [30].
-Anti-tyrosine hydroxylase (TH) antibody (Incstar, Stillwater,
MN, USA) [31], at a 1:1,000 concentration. Secondary antibody
labeled with Cy2 (green).
The sections were examined under a microscope (Olympus
Provis AX70) coupled to a digital camera (XM10, Olympus). The
images were coded green (Cy2) and red (Cy3), giving yellow co-
localization in merged images. The images were adjusted for
brightness, contrast and colors using Adobe Photoshop 7.0 (Adobe
Systems) [27].
Statistical Analysis
Data were presented as mean 6 standard deviation and
analyzed by one-way analysis of variance (ANOVA) and Tukey’s
Multiple Comparison Test using GraphPad Prism v. 5. Only
values with P,0.05 were accepted as significant.
Results and Discussion
Preparation of the DG4.5-Risp Complex
The methodology with the highest drug incorporation efficiency
proved to be that related to the following parameters:
2.461023 mmoles of DG4.5+0.24 mmoles of Risp
(DG4.5:Risp 1:100 mol:mol).
A chloroform:methanol 50:50 v/v solution with HCl 0.1N
added to a final pH of 3 (30 ml/ml incubation solution).
Film recomposition in 100 ml buffer PBS 2X.
Figure 5 shows the results obtained for the complexation of Risp
with DG4.5, where 35 to 45 drug molecules per DG4.5 were
incorporated.
The incubation solution percentage of solvents varied, and so
the polarity changed. The greatest incorporation of Risp was
obtained for the mixture chloroform:methanol 50:50 v/v solution.
Different pH conditions were then tested (pH 3–9) within the
incubation solution in order to allow the highest incorporation of
drug complexes in a 1:100 molar ratio DG4.5:Risp and the
incubation solvent composition of 50:50 chloroform:methanol
50:50 v/v solution. The solubility of the drug increased signifi-
cantly at pH 3 (46 DG4.5-Risp molecules), proving that this is the
optimum condition to obtain the DG4.5-Risp complex (Figure 6).
Finally, we analyzed whether, after the centrifuge vacuum
drying operation, there were still remaining traces of organic
solvents that could generate great variability in the amount of drug
incorporated. No significant differences were observed between
samples with and without the additional drying operation
(Figure 7).
In a previous work where we examined the complexation of
DG4 with Risp in different solvents, we found that in high ionic
strength (1 M NaCl) few molecules of Risp were incorporated in
each DG4 molecule. By simulation methodology, Welch and
Muthukumar [32] determined that the density of dendritic profiles
is suitable from that of dense core to that of a dense shell with salt
concentration or pH modification. In addition, it has been
reported that the nature of the intramolecular density profile
and the position of the terminal groups are critical in utilizing
dendrimers as drug hosts in controlled release systems [33,34].
Ideally, to incorporate a drug, the branches of dendrimers should
be highly extended. In the ionic strength tested in our previous
work, this was not the case, and DG4 was not capable of
incorporating a great number of drug molecules. This is consistent
with data published by Ma et al. (2007) [34], who found that salt
concentration is related to large changes in DG4 molecular
conformation and decreased drug incorporation. The same trend
was observed with solvent polarity [35]. It is known that the
compact structures of the hydrophobic dendrimers presenting low
accessibility to the hydrophobic pockets are favored by high
polarity solvents [36].
For our particular system, i.e. hydrophilic dendrimers and Risp,
we found that the best combination of solvents was chloroform:-
methanol 50:50 v/v pH 3, which rendered 45 molecules of Risp
per DG4.5. However, the 50:50 condition presented minimal
deviation. In this sense, methanol is necessary to stabilize the
Figure 6. Optimization of incubation parameters. Moles of Risp
per mole of DG4.5; data obtained from incubation solutions of
chloroform:methanol 50:50 v/v in different pH conditions.
doi:10.1371/journal.pone.0090393.g006
Figure 7. Moles of Risp per mole of DG4.5. Data from
incubation with different chloroform:methanol 50:50 v/v mo-
lar ratios solutions at different pHs, subjected or not to an
additional drying process.
doi:10.1371/journal.pone.0090393.g007
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carboxyl-surface, but a non-polar solvent should also be present to
improve the drug partitioning between the solvent and the inner
hydrophobic pocket of the dendrimer, which will be wide open to
incorporate the drug, but partially close to retain it. However, at
100% chloroform, no drug incorporation is achieved, since the
drug partitions better in the highly non-polar solvent than in the
hydrophobic DG4.5 pocket, and as the solvent is non-polar,
DG4.5 compaction is expected and no drug entrapment in the
hydrophobic DG4.5 inner can be achieved.
Finally, anionic DG4.5 is a weak acid capable of deprotonating
the carboxyl ending of its branching points under physiological pH
[37]. The branching points exhibit open conformations at low pH,
due to the electrostatic repulsion between the superficial groups,
which force branches to move away from each other. At pHs
higher than 9, the branches come closer again as a consequence of
the hydrogen bonds between the tertiary amines of the interior
and the carboxyl ending group portioned of the surface, resulting
in a compact structure [38]. Based on the results obtained in this
work, we can conclude that the amount of Risp incorporated to
DG4.5 is inversely proportional to pH values, which is also
consistent with the literature.
DG4.5-Risp Complex Stability
In contrast to that shown by free Risp, the release profile of the
drug complexed with DG4.5 showed that the dendrimers
functioned as nanocarriers (Figure 8). DG4.5-Risp complexes
resulted in a 45.08% release in contrast to the 62.52% release of
the free drug, after 24 h.
Characterization of DG4.5-Risp Complexes
Figure 9 A shows the FTIR spectrum of the solid drug Risp.
The bands observed correspond to the vibrational mode of the
amide NH group at 3280 cm21 and the corresponding bending at
1635 cm21. The band of the aromatic ring movement around
1014 cm21 is also present. The bands observed are also those
related to stretching vibration of the CH2 group at 2922 and
2953 cm21.
On the other hand, the FTIR spectrum of DG4.5 (Figure 9 B)
showed an absorbance peak at 2873 cm21, corresponding to the
vibrational motion of the terminal carboxyl groups and a strong
double band related to a symmetric vibrational motion of the
carboxylate at 1568 cm21. The spectrum also showed bands
corresponding to the vibrational mode of the amide group NH at
3284 cm21 and 1635 cm21, corresponding to the flexion group.
In addition, movements due to CH bonds, related to the
dendrimer backbone chain within the core of DG4.5, were
observed at 1558 cm21.
The FTIR spectrum for the DG4.5-Risp complex (Figure 9 C)
showed several differences when compared with the control
spectrum. The most interesting change was that of the band shift
of the -CH2 binding at 2945 cm
21, indicating the presence of
hydrophobic interactions in the sample analyzed. We also
observed a less pronounced shift of the amide band at
3277 cm21, and several bands, especially at 1120 and
1080 cm21, due to the stretching vibration of the carbonyl group
CO bound, strongly indicating hydrophobic interactions between
the dendrimers and the drug [7]. The resultant of dynamic light
scattering of complexes wase the three indicated peaks of
multimodal distribution, which diameters reached an average of
6.099 nm and 454.6 nm. The last peak indicates complex
aggregates. Anionic dendrimers like DG4.5 often have zeta
potentials more negative than 230 mV [39], we found that
DG4.5-Risp complexes had a zeta potential of 5.83 mV, due to
the conversion of the dendrimers’ surface carboxyl groups with
Risp molecules. This close to neutral charge could be responsible
for the formation of aggregates [40–42].
In Vivo Toxicity
Airhart et al. (2007) [43] exposed zebrafish embryos to seven
different fluoxetine (a serotonin reuptake inhibitor) concentrations
beginning at 10 hpf and up to 11 days post fertilization (dpf) to
determine the lowest observable effective concentration (LOEC).
In larvae exposed to 4.6 mM fluoxetine for 24-h intervals between
4 and 5 dpf, spontaneous swimming activity was significantly
depressed compared to controls and remained depressed ones
through 14 dpf. In addition, the core neuronal migration raphe to
the spinal cord was observed between 3 and 6 dpf [43] and
variations in the serotonin levels may affect the normal develop-
ment of the central nervous system (CNS).
Based on the observations obtained in our previous work [27],
we selected the concentrations to be used in the present work.
Heart Rate Measurements
The effect of Risp exposure on circulation was qualitatively
evaluated by observing the heart rate and blood flow through the
ventral aorta-posterior cardinal vein channel in control versus
treated larvae. These parameters provide an idea of the effects
caused by free Risp and the DG4.5-Risp complex in early
development stages and knowledge on the area of neuropharma-
cology. Here, we determined whether Risp or DG4.5-Risp
affected blood circulation. To this end, 4 and 6 dpf larvae were
exposed to 5 mM Risp or DG4.5-Risp for 24 h and their heart rate
monitored at 8 and 9 dpf. Treated larvae exhibited normal heart
rate as compared to controls (data not shown).
Tissue Sections
i- Morphological Changes. Both treated and control
animals were fixed at 10 dpf, cut in serial sections and stained,
as detailed in the Experimental Section. A 24-h exposure to
risperidone or DG4.5-Risp on 4 dpf resulted in a larger area in the
postoptic commissure and the raphe population zone and a
cellular disorganization in the latter. This effect was observed in all
treatments, but higher in animals treated with free Risp (Figure 10).
Undoubtedly, the administration of this drug to animals at 4 dpf
caused dramatic changes that persisted over time.
ii- Immunohistochemistry. For the histological analysis,
crop images were obtained to include reference space area and
optical angle for brain tissue. We used tyrosine hydroxylase (TH)
Figure 8. Release profile of the drug complexed to DG4.5. The
graph indicates the percentage of drug released when found in
the dendrimers or free form.
doi:10.1371/journal.pone.0090393.g008
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Figure 9. Drug interaction with the dendrimer. FTIR spectrum of Risp (A), DG4.5 (B) and DG4.5-Risp (C) solid state runs.
doi:10.1371/journal.pone.0090393.g009
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to label dopaminergic neurons and calretinin (CalR) to label
motoneurons.
When the larvae were exposed to free Risp at 4 dpf, an increase
in CalR-positive motoneurons was observed in the brain
(Figure 11). The other treatments showed no changes in brain
tissue with respect to controls (Figure 11).
The spinal cord showed a decrease in CalR-positive motoneu-
rons in treatments with Risp alone (Figure 12). The other
treatments showed no changes in brain tissue with respect to
controls (Figure 12).
Several antipsychotic drugs produce a neurotoxic mechanism
resulting from an increased or decreased concentration of
serotonin both in the synaptic and extracellular spaces. In this
sense, drug exposure at 4 or 5 dpf coincides with the initial
appearance of raphe axons distributed throughout the entire
length of the spinal cord in zebrafish [43]. Growth cones of these
axons at 4 dpf were observed adjacent to reticulospinal neurons in
the hindbrain and secondary motoneurons in the spinal cord. The
temporal correlation between the growth of inferior raphe axons
and growth cones throughout the spinal cord and the earliest
morphological effects of antipsychotic drugs suggested that raphe
Figure 10. Images of histological sections of brain tissue stained with hematoxylin-eosin. A) control, B) risperidone (Risp) at 4 dpf, C) Risp
at 6 dpf, D) DG4.5-Risp at 4 dpf, and E) DG4.5-Risp at 6 dpf. Larvae were analyzed three times (n = 3) at 10 dpf.
doi:10.1371/journal.pone.0090393.g010
Figure 11. Immunohistochemistry images of brain tissue. Tyrosine hydroxylase, labeled with Cy2 (green), and Calretinin, labeled with Cy3
(red). A) control, B) risperidone (Risp) at 4 dpf, C) Risp at 6 dpf, D) DG4.5-Risp at 4 dpf, and E) DG4.5-Risp at 6 dpf. Larvae were analyzed three times
(n = 3) at 10 dpf.
doi:10.1371/journal.pone.0090393.g011
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axons were affected by the exposure to these drugs. However, the
mechanism of toxicity by excess or deficit of serotonin was difficult
to determine.
Antipsychotic drugs could alter extracellular levels of neuro-
transmitters and thereby modify the development of the CNS [43–
46]. These changes suggest that the neuroanatomy is severely
affected by exposure to free Risp but to a lesser extent than by
DG4.5-Risp.
Conclusions
Development of molecular nanostructures with well-defined
particle sizes is of increasing interest in biomedical applications
[6,47–49]. Dendrimers, like other delivery systems, offer attractive
properties that allow modifying the pharmacokinetics and
bioavailability of drugs. These changes depend not only on the
class of dendrimer, but also on the physicochemical nature of the
complex that the dendrimer forms with the drug. Drugs can be
complexed with dendrimers through encapsulation into void
spaces (nanoscale container), association with the surface groups
(nano-scaffolding), or both [6,50]. The high density of surface
groups (one amino group/nm2 for DG4) combined with the small
size (4.5 nm diameter for the DG4 ellipsoids) result in a high area/
volume ratio [51,52], which can be modified controlling the
environment ionic strength, pH, temperature, etc.
In summary, here we described the preparation, stability and
characterization of the DG4.5-Risp complex. The best dendrimer-
risperidone incorporation (46 risperidone molecules per dendri-
mer) was achieved with a mixture of chloroform:methanol
50:50 v/v pH 3.
Then, we determined the in vivo effects of risperidone and
DG4.5-Risp on the heart rate and brain development in zebrafish
larvae. The most significant changes were observed when free
risperidone was administered, but no changes were observed when
larvae were treated with the complex. This could indicate a
decrease in the side effects of the drug when administered as a
complex, or a decrease in the effectiveness and/or arrival of the
complex. Certainly, more studies are necessary to determine
whether the complexed drug reaches the brain.
Supporting Information
Video S1 Heart Rate Measurements. The heart rate was
assessed on 8 and 10 dpf. Control and experimental zebrafish
larvae were individually transferred to a depression slide with
methylcellulose and placed under a binocular microscope. The
heart rate was determined by counting the number of beats every
15 s and recorded as beats per minute.
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